Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.

Clinical lung cancer - 1 Jul 2013

Sun Hai-bo, Ou Wei, Li Yin, Fang Qin, Qin Jianjun, Zhang Liang, Wang Si-yu

Abstract excerpt

INTRODUCTION: This study was to assess the association of epidermal growth factor receptor (EGFR) mutation status and efficacy of adjuvant chemotherapy in patients with fully resected IIIA-N2 non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: Tumor samples (n = 150) from patients with IIIA-N2 NSCLC who either had or had not received paclitaxel plus carboplatin or vinorelbine plus carboplatin doublet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Paclitaxel

Share to Small Cell Lung Carcinoma

Share to Survival Rate

Share to Vinblastine

Share to Vinorelbine

Source

Identifiers

PMID: 23291256
DOI: 10.1016/j.cllc.2012.10.008

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.PMID 23291256Read ↗

Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.Semantic proximity Read ↗

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and FutureSemantic proximity Read ↗

Efficacy and safety of adjuvant EGFR-TKIs for non-small cell lung cancer with EGFR mutations after surgery: an updated meta-analysisSemantic proximity Read ↗

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.Semantic proximity Read ↗

Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.Semantic proximity Read ↗

EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study.Semantic proximity Read ↗

The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer.Semantic proximity Read ↗

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.Semantic proximity Read ↗

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.